Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q08357
UPID:
S20A2_HUMAN
Alternative names:
Gibbon ape leukemia virus receptor 2; Phosphate transporter 2; Solute carrier family 20 member 2
Alternative UPACC:
Q08357
Background:
Sodium-dependent phosphate transporter 2, also known as Gibbon ape leukemia virus receptor 2 and Phosphate transporter 2, plays a pivotal role in phosphate homeostasis. It preferentially transports the monovalent form of phosphate, crucial for bone mineralization and maintaining normal cerebrospinal fluid phosphate levels. Additionally, it mediates vascular smooth muscle cell calcification and serves as a receptor for various retroviruses.
Therapeutic significance:
The protein's involvement in Basal ganglia calcification, idiopathic, 1, characterized by brain calcifications leading to a spectrum of neuropsychiatric symptoms, underscores its therapeutic potential. Understanding the role of Sodium-dependent phosphate transporter 2 could open doors to potential therapeutic strategies for managing this condition and related phosphate homeostasis disorders.